Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 11/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 5/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | CA3 | P07451 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29519425 | 1.00 | MEN1 (0.39) | MEN1KMT2ANR3C1NR3C2PTGS1 | |
| SCHEMBL30848125 | 0.83 | KMT2A (0.39) | MEN1KMT2ANR3C1NR3C2PTGS1 | |
| SCHEMBL1344537 | 0.83 | KMT2A (0.39) | MEN1KMT2ANR3C1NR3C2PTGS1 | |
| SCHEMBL278305 | 0.83 | PTGS1 (0.39) | MEN1KMT2ANR3C1PTGS1PTGS2 | |
| SCHEMBL29519382 | 0.81 | NR3C1 (0.36) | MEN1KMT2ANR3C1NR3C2PTGS1 | |
| SCHEMBL19693724 | 0.81 | NR3C1 (0.36) | MEN1KMT2ANR3C1NR3C2PTGS1 | |
| SCHEMBL15974121 | 0.81 | NR3C1 (0.36) | MEN1KMT2ANR3C1NR3C2PTGS1 | |
| SCHEMBL30133804 | 0.81 | NR3C1 (0.36) | MEN1KMT2ANR3C1NR3C2PTGS1 | |
| SCHEMBL18802727 | 0.80 | MEN1 (0.42) | MEN1KMT2ANR3C1NR3C2PTGS1 | |
| SCHEMBL181587 | 0.77 | PKM (0.39) | MEN1KMT2APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326764-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS LLC (US) | 2025-10-23 | — | — | US | disclosed |
| US-12312359-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2025-05-27 | — | — | US | disclosed |
| US-20230174541-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, LLC | 2023-06-08 | — | — | US | disclosed |
| US-20230174541-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, LLC | 2023-06-08 | — | — | US | disclosed |
| US-20230174541-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, LLC | 2023-06-08 | — | — | US | disclosed |
| US-11479557-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2022-10-25 | — | — | US | disclosed |
| US-11479557-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2022-10-25 | — | — | US | disclosed |
| CN-109743875-B | Inhibitors of the MENIN-MLL interaction | 生命医药有限责任公司 | 2022-04-29 | — | — | CN | disclosed |
| EP-3805215-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | Vitae Pharmaceuticals, LLC (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-3805215-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | Vitae Pharmaceuticals, LLC (US) | 2021-04-14 | — | — | EP | disclosed |
| US-20160067245-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives and Their Use For The Treatment of Prevention of Neurological and Psychiatric Disorders | JANSSEN PHARMACEUTICALS INC (US) | 2016-03-10 | — | — | US | disclosed |
| US-9226930-B2 | 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders | Janssen Pharmaceuticals, Inc. (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150141403-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives and Their Use For The Treatment of Prevention of Neurological and Psychiatric Disorders | JANSSEN PHARMACEUTICALS INC (US) | 2015-05-21 | — | — | US | disclosed |
| US-8937060-B2 | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders | Janssen Pharmaceuticals, Inc. (US) | 2015-01-20 | — | — | US | disclosed |
| US-8859112-B2 | Organic compound and organic light emitting element using the same | CANON KABUSHIKI KAISHA (JP) | 2014-10-14 | — | — | US | disclosed |
| US-8859112-B2 | Organic compound and organic light emitting element using the same | CANON KABUSHIKI KAISHA (JP) | 2014-10-14 | — | — | US | disclosed |
| EP-2430022-B1 | 1,2,4-Triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders | JANSSEN PHARMACEUTICALS INC (US) | 2013-11-20 | — | — | EP | disclosed |
| US-20130049581-A1 | NOVEL ORGANIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT USING THE SAME | CANON KABUSHIKI KAISHA (JP) | 2013-02-28 | — | — | US | disclosed |
| US-20130049581-A1 | NOVEL ORGANIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT USING THE SAME | CANON KABUSHIKI KAISHA (JP) | 2013-02-28 | — | — | US | disclosed |
| US-20120184525-A1 | 1,2,3-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THIER USE FOR THE TREATMENT OF PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ADDEX PHARMA S.A. (CH) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174541-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | MEN1 2/4885KMT2A 12/4885NR3C1 2846/4885 |
| US-12312359-B2 | Inhibitors of the menin-MLL interaction | MLLT1, MEN1, MLLT3 | MEN1 2/4885KMT2A 12/4885NR3C1 2846/4885 |
| US-20120184525-A1 | 1,2,3-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THIER USE FOR THE TREATMENT OF PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | GRM2, GRM3, GRM1 | MEN1 4699/4885KMT2A 1176/4885NR3C1 137/4885 |
| US-20160067245-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives and Their Use For The Treatment of Prevention of Neurological and Psychiatric Disorders | GRM2, GRM1, GRIN2C | MEN1 4777/4885KMT2A 988/4885NR3C1 140/4885 |
| US-11479557-B2 | Inhibitors of the menin-MLL interaction | MLLT1, MEN1, MLLT3 | MEN1 2/4885KMT2A 12/4885NR3C1 2846/4885 |
| US-20130049581-A1 | NOVEL ORGANIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT USING THE SAME | LEF1, CYP1A1, TCF7L2 | MEN1 906/4885KMT2A 2672/4885NR3C1 345/4885 |
| US-20250326764-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | MEN1 2/4885KMT2A 12/4885NR3C1 2846/4885 |
| US-20150141403-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives and Their Use For The Treatment of Prevention of Neurological and Psychiatric Disorders | GRM2, GRM1, GRIN2C | MEN1 4794/4885KMT2A 985/4885NR3C1 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.